Nanoform and Herantis Collaborate to Enhance Drug Delivery of CDNF and xCDNF Therapies

shot by IP News Shots / 6:33 pm on 18 December, 2020

Nanoform Finland Plc and Herantis Pharma Plc have signed a Letter of Intent (LoI) to collaborate on the enhancement of nasal drug delivery to the brain of therapies using nanoparticle technology. The therapies used in the collaboration are CDNF and xCDNF, which belong to Herantis and the nanoparticle technology is Nanoform’s proprietary technology. On finalization of the collaboration, as per Nanoform’s undertaking, it will invest 1600,000 Euros subject to some customary conditions.

Read More at: https://www.biospace.com/article/releases/nanoform-and-herantis-partner-to-look-for-opportunities-to-enhance-bbb-penetration-of-cdnf-and-xcdnf-molecules/

Industry: Healthcare Technology | Type of IP: Deals - Other Collaborations